Holzkirchen, June 19, 2017 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the European Commission (EC) has approved Rixathon® (biosimilar ...
Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche’s Rituxan that generated $7.5 billion in 2016 sales.
The European Commision (EC) approved Sandoz’ Rixathon ® biosimilar of Roche’s blockbuster monoclonal antibody (mAb) rituximab (MabThera ® /Rituxan ®). Rixathon is cleared in Europe for use in all ...
Sandoz, the biosimilar division of Swiss drugmaker Novartis, said the approval allows for the use of Rixathon in Europe and represents a “big win” for patients with “blood cancers or immunological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results